Polypharmacology of Approved Anticancer Drugs

被引:25
作者
Amelio, Ivano [1 ]
Lisitsa, Andrey [2 ]
Knight, Richard A. [1 ]
Melino, Gerry [1 ,3 ,4 ]
Antonov, Alexey V. [1 ,3 ]
机构
[1] Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England
[2] Russian Acad Med Sci, Inst Biomed Chem, Pogodinskaya St, Moscow, Russia
[3] Inst Cytol, St Petersburg 194064, Russia
[4] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy
基金
英国医学研究理事会;
关键词
Polypharmacology; tyrosine kinase inhibitors; histone deacetylase inhibitors; DNA topoisomerase inhibitors; tamoxifen; drug targets; rational design of multitarget drugs; TYROSINE KINASE INHIBITORS; HISTONE DEACETYLASE INHIBITORS; CELL-CYCLE; CANCER; SURVIVAL; TARGET; P53; TOOL; PERSPECTIVE; ACTIVATION;
D O I
10.2174/1389450117666160301095233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms.
引用
收藏
页码:534 / 543
页数:10
相关论文
共 65 条
[41]   Perspective on Multi-Target Antiplatelet Therapies: High Content Phenotypic Screening as an Unbiased Source of Novel Polypharmacological Strategies [J].
Landre, Vivien ;
Amelio, Ivano ;
Barlev, Nick A. ;
Knight, Richard A. ;
Lisitsa, Andrey ;
Melino, Gerry ;
Antonov, Alexey V. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2015, 15 (08) :622-629
[42]   Endocrine side effects of broad-acting kinase inhibitors [J].
Lodish, Maya B. ;
Stratakis, Constantine A. .
ENDOCRINE-RELATED CANCER, 2010, 17 (03) :R233-R244
[43]   p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling [J].
Memmi, Elisa Maria ;
Sanarico, Anna Giulia ;
Giacobbe, Arianna ;
Peschiaroli, Angelo ;
Frezza, Valentina ;
Cicalese, Angelo ;
Pisati, Federica ;
Tosoni, Daniela ;
Zhou, Huiqing ;
Tonon, Giovanni ;
Antonov, Alexey ;
Melino, Gerry ;
Pelicci, Pier Giuseppe ;
Bernassola, Francesca .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (11) :3499-3504
[44]   Encountering unpredicted off-target effects of pharmacological inhibitors [J].
Miyazawa, Keiji .
JOURNAL OF BIOCHEMISTRY, 2011, 150 (01) :1-3
[45]   Regulation of ERBB3/HER3 signaling in cancer [J].
Mujoo, Kalpana ;
Choi, Byung-Kwon ;
Huang, Zhao ;
Zhang, Ningyan ;
An, Zhiqiang .
ONCOTARGET, 2014, 5 (21) :10222-10236
[46]   Mutant p53 in Cancer: New Functions and Therapeutic Opportunities [J].
Muller, Patricia A. J. ;
Vousden, Karen H. .
CANCER CELL, 2014, 25 (03) :304-317
[47]   p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling [J].
Nayak, G. ;
Cooper, G. M. .
CELL DEATH & DISEASE, 2012, 3 :e400-e400
[48]   How to improve R&D productivity: the pharmaceutical industry's grand challenge [J].
Paul, Steven M. ;
Mytelka, Daniel S. ;
Dunwiddie, Christopher T. ;
Persinger, Charles C. ;
Munos, Bernard H. ;
Lindborg, Stacy R. ;
Schacht, Aaron L. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (03) :203-214
[49]   Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation [J].
Pieraccioli, Marco ;
Imbastari, Francesca ;
Antonov, Alexey ;
Melino, Gerry ;
Raschella, Giuseppe .
CELL CYCLE, 2013, 12 (14) :2309-2320
[50]   DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs [J].
Pommier, Yves ;
Leo, Elisabetta ;
Zhang, HongLiang ;
Marchand, Christophe .
CHEMISTRY & BIOLOGY, 2010, 17 (05) :421-433